Ocugen, Inc.
OCGNNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | $500,000 | $0 | $43,000 |
| Operating income | −$62.9M | −$54.8M | −$65.5M | −$19.0M | −$58.0M | −$21.3M |
| Net income | −$67.8M | −$54.1M | −$63.1M | −$19.0M | −$58.4M | −$21.8M |
| Total assets | $43.5M | $82.4M | $64.5M | $141.7M | $105.8M | $27.4M |
| Total liabilities | $55.7M | $52.8M | $24.0M | $16.2M | $9.9M | $5.8M |
| Equity | −$12.2M | $29.6M | $40.6M | $74.0M | $91.2M | $21.6M |
| EPS (diluted) | — | — | $-0.08 | $-0.09 | $-0.30 | $-0.31 |
| Shares out. | 292.0M | 257.3M | 226.4M | 199.5M | 188.1M | 52.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1425.7%
- Net margin
- −1537.4%
- Return on equity
- 557.7%
- Return on assets
- −155.9%
- Return on capital (ROCE)
- −307.3%
- Liabilities / assets
- 128.0%
- Debt / equity
- —
- Book value / share
- $-0.04
- Revenue growth (YoY)
- 8.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -40.32distress
- Accruals / assets
- −25.0%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-02-17Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- Phase 1Recruitingreadout ~2026-07-31Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Phase 2/3Active Not Recruitingreadout ~2026-09-28A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
- Phase 3Active Not Recruitingreadout ~2027-02-12A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
- Phase 1/2Active Not Recruitingreadout ~2027-03Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Millennium Management LlcPassive (13G)Apr 14, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Janus Henderson Group PlcPassive (13G)Dec 8, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- State Street CorpPassive (13G)Feb 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 81.0M | 8.2 | +16.3% |
| Apr 30, 2026 | 69.7M | 11.6 | +2.6% |
| Apr 15, 2026 | 67.9M | 12.4 | +4.8% |
| Mar 31, 2026 | 64.8M | 5.3 | +23.7% |
| Mar 13, 2026 | 52.4M | 4.2 | +3.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventMay 14, 2026
- New financial obligation · Unregistered equity sale · Regulation FD disclosureMay 14, 2026
- Entered a material agreement · Terminated a material agreement · Results of operations · New financial obligation · Unregistered equity saleMay 7, 2026
- Results of operations · Other material eventMay 5, 2026
- Results of operations · Regulation FD disclosure · Other material eventMay 4, 2026
- Regulation FD disclosureMar 27, 2026
- Regulation FD disclosureMar 24, 2026
- Other material eventMar 20, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 14, 2026
- 8-KFORM 8-KMay 14, 2026
- 10-QMay 8, 2026
- 8-KFORM 8-KMay 7, 2026
- 8-KFORM 8-KMay 5, 2026
- 8-KFORM 8-KMay 4, 2026
- DEFA14AApr 28, 2026
- ARSApr 28, 2026
- DEF 14AApr 28, 2026
- PRER14AApr 20, 2026
- PRE 14AApr 17, 2026
- SCHEDULE 13GApr 14, 2026
- 4OWNERSHIP DOCUMENTApr 2, 2026
- SCHEDULE 13G/AMar 27, 2026
- 8-KMar 27, 2026